<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33859435</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Altered perivascular fibroblast activity precedes ALS disease onset.</ArticleTitle><Pagination><StartPage>640</StartPage><EndPage>646</EndPage><MedlinePgn>640-646</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01295-9</ELocationID><Abstract><AbstractText>Apart from well-defined factors in neuronal cells<sup>1</sup>, only a few reports consider that the variability of sporadic amyotrophic lateral sclerosis (ALS) progression can depend on less-defined contributions from glia<sup>2,3</sup> and blood vessels<sup>4</sup>. In this study we use an expression-weighted cell-type enrichment method to infer cell activity in spinal cord samples from patients with sporadic ALS and mouse models of this disease. Here we report that patients with sporadic ALS present cell activity patterns consistent with two mouse models in which enrichments of vascular cell genes preceded microglial response. Notably, during the presymptomatic stage, perivascular fibroblast cells showed the strongest gene enrichments, and their marker proteins SPP1 and COL6A1 accumulated in enlarged perivascular spaces in patients with sporadic ALS. Moreover, in plasma of 574 patients with ALS from four independent cohorts, increased levels of SPP1 at disease diagnosis repeatedly predicted shorter survival with stronger effect than the established risk factors of bulbar onset or neurofilament levels in cerebrospinal fluid. We propose that the activity of the recently discovered perivascular fibroblast can predict survival of patients with ALS and provide a new conceptual framework to re-evaluate definitions of ALS etiology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>M&#xe5;nberg</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0056-1313</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Skene</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Folkert</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trusohamn</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0541-8903</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remnest&#xe5;l</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczepi&#x144;ska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksoylu</LastName><ForeName>Inci Sevval</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;nnerberg</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebarasi</LastName><ForeName>Lwaki</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wouters</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5243-6186</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olofsson</LastName><ForeName>Jennie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8593-9089</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Gohren Antequera</LastName><ForeName>Inti</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domaniku</LastName><ForeName>Aylin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7785-2143</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Schaepdryver</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2480-863X</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurobiomarker Research, Department of Neurology, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department and Center for Brain &amp; Disease Research, KU Leuven, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Neurobiomarker Research, Department of Neurology, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine, UZ Leuven (University Hospital Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhl&#xe9;n</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4858-8056</Identifier><AffiliationInfo><Affiliation>Division of Systems Biology, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anink</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mijnsbergen</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergunst-Bosch</LastName><ForeName>Hermieneke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMC Utrecht Brain Center, University Medical Center Utrecht, Department of Neurology, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;bers</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Ulm, Neurology Clinic, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kl&#xe4;ppe</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-5832-038X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Vieitez</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilthorpe</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-6884-4774</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedlund</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6347-0075</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-4990-509X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Neurology Department and Center for Brain &amp; Disease Research, KU Leuven, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Ulm, Neurology Clinic, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), Ulm, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>UMC Utrecht Brain Center, University Medical Center Utrecht, Department of Neurology, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4657-8532</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Sebastian A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-5935-0211</Identifier><AffiliationInfo><Affiliation>Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden. sebastian.lewandowski@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden. sebastian.lewandowski@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.11632794</AccessionNumber><AccessionNumber>10.6084/m9.figshare.11635887</AccessionNumber><AccessionNumber>10.6084/m9.figshare.11628891</AccessionNumber><AccessionNumber>10.6084/m9.figshare.11628585</AccessionNumber><AccessionNumber>10.6084/m9.figshare.14035616</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>108726</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>108726/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C553839">Col6a1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024142">Collagen Type VI</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506895">SPP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2021 Apr;27(4):585-586</RefSource><PMID Version="1">33859434</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2021 Jul;27(7):1308</RefSource><PMID Version="1">34079107</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024142" MajorTopicYN="N">Collagen Type VI</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066253" MajorTopicYN="N">Vascular Remodeling</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests.</b> We declare that the authors do not have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33859435</ArticleId><ArticleId IdType="mid">EMS151802</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01295-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cook C, Petrucelli L. Genetic Convergence Brings Clarity to the Enigmatic Red Line in ALS. Neuron. 2019;101:1057&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci. 2018;21:329&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski SA, et al. Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol. 2016;131:453&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839168</ArticleId><ArticleId IdType="pubmed">26687981</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-H, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16:571&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, et al. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science (80-) 2015;347:1138&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques S, et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science (80-) 2016;352:1326&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221728</ArticleId><ArticleId IdType="pubmed">27284195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, et al. Molecular Architecture of the Mouse Nervous System. Cell. 2018;174:999&#x2013;1014.:e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, Grant SGN. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front Neurosci. 2016;10:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark JA, Southam KA, Blizzard CA, King AE, Dickson TC. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Chem Neuroanat. 2016;76:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">27038603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Hong SY, Kliot M, M&#xf6;ller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport. 2003;14:1051&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12802201</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A Neurodegeneration-Specific Gene-Expression Signature of Acutely Isolated Microglia from an Amyotrophic Lateral Sclerosis Mouse Model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc Natl Acad Sci U S A. 2015;112:E6993-7002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Ineichen BV, Detmar M, Proulx ST. Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. Nat Commun. 2017;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681558</ArticleId><ArticleId IdType="pubmed">29127332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor KG, Katz SE, Grzybowski DM, Lubow M. Cerebrospinal fluid outflow: An evolving perspective. Brain Res Bull. 2008;77:327&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">18793703</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019;29:1164&#x2013;1177.:e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, et al. Amyotrophic lateral sclerosis&#x2014;a model of corticofugal axonal spread. Nat Publ Gr. 2013;9:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu AY, et al. Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis. Mol Cell Neurosci. 1995;6:349&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">8846004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, et al. Inflammatory markers in cerebrospinal fluid : independent prognostic biomarkers in amyotrophic lateral sclerosis? 2019:1&#x2013;9. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Talbot K, Goldacre MJ. Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis: Table 1. J Neurol Neurosurg Psychiatry. 2016;87:244&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789816</ArticleId><ArticleId IdType="pubmed">26260352</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton FC, Trabjerg BB, Wray NR, Agerbo E. Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis. Eur J Neurol. 2020:1&#x2013;10. doi: 10.1111/ene.14554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14554</ArticleId><ArticleId IdType="pubmed">32978838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule RR, Schuff N, Miller RG, Weiner MW. Gray matter perfusion correlates with disease severity in ALS. Neurology. 2010;74:821&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839193</ArticleId><ArticleId IdType="pubmed">20147656</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MJ, et al. Widespread cerebral haemodynamics disturbances occur early in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:202&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22292841</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236:327&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">25128758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiocchetti A, et al. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. J Immunol Res. 2016;2016:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206443</ArticleId><ArticleId IdType="pubmed">28097158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9:356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834520</ArticleId><ArticleId IdType="pubmed">29500465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, et al. Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia. JAMA Neurol. 2017;74:1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5695230</ArticleId><ArticleId IdType="pubmed">28715552</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeijer D, Ikram MK, Hilal S. Enlarged Perivascular Spaces and Dementia: A Systematic Review. J Alzheimer&#x2019;s Dis. 2019;72:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839481</ArticleId><ArticleId IdType="pubmed">31561362</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R, et al. Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res. 2018;114:1462&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455920</ArticleId><ArticleId IdType="pubmed">29726891</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG, Grant SGN. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front Neurosci. 2016;10:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman BJ, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1 G93A mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012;2:563&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489809</ArticleId><ArticleId IdType="pubmed">23139902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009;4:1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47-e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin SJ, et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. Hum Mol Genet. 2009;19:313&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796893</ArticleId><ArticleId IdType="pubmed">19864493</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbor B. Working with ALS Mice. Jax. 2009:1&#x2013;28.</Citation></Reference><Reference><Citation>Ludolph A, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Front Degener. 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet EA, et al. Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. J Neuropathol Exp Neurol. 2020;79:266&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036662</ArticleId><ArticleId IdType="pubmed">31999342</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011;179:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg &amp;amp; Psychiatry. 2011;82:1165 LP-1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin N, et al. The Swedish motor neuron disease quality registry. 2018 doi: 10.1080/21678421.2018.1497065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497065</ArticleId><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk JM, Gry M, Rimini R, Uhl&#xe9;n M, Nilsson P. Antibody Suspension Bead Arrays within Serum Proteomics. J Proteome Res. 2008;7:3168&#x2013;3179.</Citation><ArticleIdList><ArticleId IdType="pubmed">18588325</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;ggmark A, et al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1:544&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184557</ArticleId><ArticleId IdType="pubmed">25356426</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>